We have now discovered that aspirin plays a crucial role in overcoming osimertinib resistance by inhibiting phosphorylation of Akt/FoxO3a signaling components and up‐regulating Bim protein synthesis in osimertinib‐resistant EGFR‐mutated NSCLC cells. Here, AKT1 is linked to non-small cell lung carcinoma.